Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
NCT07078838 on ClinicalTrials.gov · last registry update 2026-09-28
A small phase 2 — 40 participants, against a typical 110. Due to report March 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Anti-proliferative effect of Tirzepatide. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2027-01
- Primary completion
- 2029-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Anti-proliferative effect of Tirzepatide
Conditions studied
Endometrial Cancer · Endometrial Intraepithelial Neoplasia · Grade 1 Endometrial Endometrioid Carcinoma
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.